In 2018, a British woman named Karin Sieger wrote about her experience in an emergency room. She had arrived with crushing chest pain, nausea, and shortness of breath. A nurse took her vitals, then told her she was probably having a panic attack. She was sent home with a leaflet about anxiety management. She was having a heart attack.
Sieger's story is not an outlier. A 2022 study published in The Lancet found that women presenting to emergency departments with acute coronary syndromes were 50% more likely than men to receive an initial misdiagnosis. A separate analysis of over 20,000 Danish patients, published in Nature Medicine in 2019, found that women were diagnosed later than men across more than 700 diseases, with delays averaging over four years for conditions like diabetes and cancer.
These are not anecdotes. They are symptoms of a systemic problem woven into the foundations of modern medicine. For most of its history, medical research has treated the male body as the default human body. Textbook anatomy is male anatomy. Standard drug dosages are calibrated to male weight and metabolism. Diagnostic criteria for conditions like heart disease, ADHD, and autism were developed from studies conducted overwhelmingly or exclusively on men. When women present with symptoms that do not match the male template, the system does not recognize what it is looking at.
This article examines the evidence: where the gender gap in healthcare comes from, how it manifests in diagnosis, treatment, and research, and what women can do to navigate a system that was not designed for them.
The Clinical Trial Problem: Built on Male Bodies
The gender gap in healthcare has its roots in who gets studied. For decades, clinical trials — the gold standard for developing treatments — systematically excluded women.
The reasons were partly regulatory and partly cultural. After the thalidomide disaster of the 1960s, the US Food and Drug Administration issued guidelines in 1977 that recommended excluding women of "childbearing potential" from early-phase clinical trials, citing concerns about harm to a potential fetus. The guideline was well-intentioned but had a sweeping consequence: for the next 16 years, the vast majority of pharmaceutical research was conducted on men.
Even beyond the FDA's exclusion policy, researchers preferred male subjects for practical reasons. Male hormone levels do not fluctuate on a monthly cycle, making data "cleaner" and easier to analyze. Female physiology was treated as a confounding variable — noise to be eliminated rather than biology to be understood.
The FDA reversed its exclusion policy in 1993, and the National Institutes of Health Revitalization Act of the same year mandated that federally funded clinical trials include women and minorities. But change has been slow. A 2020 analysis in The New England Journal of Medicine examined 20 years of cardiovascular trials and found that women still represented only 38% of participants on average — despite cardiovascular disease being the leading cause of death for women globally. A 2022 review in JAMA Network Open found similar underrepresentation in trials for cancer, neurology, and metabolic disease.
The consequences are not abstract. Drugs are metabolized differently in female bodies due to differences in body composition, liver enzymes, kidney function, and hormonal environment. Women generally have a higher percentage of body fat, lower body water volume, and different expression of cytochrome P450 enzymes — all of which affect how drugs are absorbed, distributed, and cleared. A 2020 study in Biology of Sex Differences found that women experienced adverse drug reactions nearly twice as often as men, attributing much of the difference to dosages developed using male-predominant study populations. Eight of the ten drugs withdrawn from the US market between 1997 and 2001 posed greater health risks for women than for men.
The Heart Attack That Looks Like Anxiety
Nowhere is the gender diagnostic gap more dangerous than in cardiovascular disease.
Heart disease kills more women than all cancers combined. Yet for decades, it has been framed as a "man's disease" in both medical education and public consciousness. The classic heart attack presentation — crushing central chest pain radiating to the left arm — was identified in studies of men. Women frequently present differently: with fatigue, nausea, jaw pain, back pain, or shortness of breath rather than the textbook chest-clutching scenario.
A 2021 study in Circulation, the journal of the American Heart Association, analyzed over 2 million emergency department visits and found that women with acute myocardial infarction were significantly less likely than men to receive an electrocardiogram within the recommended 10-minute window. The delay was not due to women arriving later — it was due to triage assessments that rated their symptoms as lower priority.
The consequences are measurable in mortality. A 2019 study published in The BMJ found that women who were treated by female physicians in the emergency department had significantly better survival outcomes than those treated by male physicians. The researchers hypothesized that female physicians were more likely to recognize atypical presentations. A follow-up analysis suggested that male physicians' outcomes improved when they had more female colleagues on staff — exposure to diverse clinical perspectives changed diagnostic behavior.
The pattern extends beyond heart attacks. A 2018 analysis in the European Heart Journal found that women with heart failure were less likely to be prescribed guideline-recommended therapies, including ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. They were also less likely to be referred for cardiac rehabilitation, despite evidence that rehabilitation reduces mortality equally in both sexes.
The Pain Bias: "It's All in Your Head"
Ask almost any woman about her experience with the medical system and you will hear a version of the same story: symptoms described clearly, then minimized, psychologized, or dismissed.
This pattern has a name in the research literature: diagnostic overshadowing — when a patient's symptoms are attributed to a psychogenic cause (anxiety, depression, stress, hysteria) rather than investigated for an organic one. Studies consistently show that this happens disproportionately to women.
A foundational 2001 study by Hoffmann and Tarzian, published in The Journal of Law, Medicine & Ethics, reviewed decades of pain research and found that women were more likely to be prescribed sedatives and antidepressants for pain, while men presenting with identical symptoms were more likely to receive analgesics. The phenomenon was dubbed the "Yentl syndrome" — a reference to the Barbra Streisand film in which a woman must disguise herself as a man to be taken seriously.
More recent data confirms the pattern persists. A 2021 study in PNAS (Proceedings of the National Academy of Sciences) used standardized case vignettes — identical descriptions of symptoms presented as either a male or female patient — and found that healthcare providers rated women's pain as less intense and were less likely to recommend aggressive treatment. The bias was present in both male and female clinicians, suggesting it is embedded in medical culture rather than individual attitudes.
The consequences are especially severe for conditions that disproportionately affect women. Autoimmune diseases — 80% of which occur in women, according to the American Autoimmune Related Diseases Association — take an average of 4.6 years and 4 different doctors to diagnose. Lupus, fibromyalgia, multiple sclerosis, and rheumatoid arthritis all have well-documented diagnostic delays in women, with symptoms frequently attributed to stress, depression, or hypochondria before the underlying condition is identified.
Endometriosis: A Case Study in Diagnostic Failure
If one condition encapsulates everything wrong with how medicine treats women's health complaints, it is endometriosis.
Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus — on the ovaries, fallopian tubes, bowel, bladder, and other pelvic structures. It affects an estimated 190 million women and girls worldwide according to the World Health Organization, roughly 10% of reproductive-age women. The primary symptom is pain: debilitating menstrual cramps, chronic pelvic pain, pain during intercourse, and pain during bowel movements or urination.
Despite its prevalence and severity, the average time from symptom onset to diagnosis is 7 to 10 years. A 2019 study in The American Journal of Obstetrics and Gynecology found the mean diagnostic delay was 8.6 years in the United Kingdom and 11.7 years in the United States. During this delay, patients typically see an average of 7 physicians and receive multiple incorrect diagnoses including irritable bowel syndrome, pelvic inflammatory disease, or — most commonly — are told their pain is "normal period pain" that they need to manage.
The diagnostic delay is not due to the condition being undetectable. Endometriosis can often be strongly suspected based on symptoms, clinical exam, and imaging. The delay stems from a combination of factors: normalization of menstrual pain in both culture and clinical training, lack of emphasis on endometriosis in medical education, absence of a simple non-invasive diagnostic test (definitive diagnosis currently requires laparoscopy), and the persistent tendency to dismiss women's pain reports.
Research funding reflects the same neglect. A 2020 analysis in BMJ Open compared disease burden with NIH funding allocation and found that endometriosis received roughly $7 per affected patient per year in research funding — compared to $35 for diabetes and $100 for Crohn's disease, despite endometriosis affecting a far larger population.
Beyond Reproductive Health: The Gap in Every Specialty
It would be a mistake to think the gender gap is confined to obstetrics and gynecology. It runs through nearly every medical specialty.
Cardiology. As discussed above, women's heart disease is underdiagnosed and undertreated. But the gap extends to stroke as well. A 2020 study in Stroke found that women experiencing acute stroke waited an average of 11 minutes longer to receive brain imaging in the emergency department compared to men, and were less likely to receive thrombolytic therapy within the guideline window.
Psychiatry and neurology. ADHD in women is dramatically underdiagnosed. The condition was historically studied almost exclusively in hyperactive boys, and diagnostic criteria still reflect that bias. Women with ADHD are more likely to present with inattentive symptoms — difficulty concentrating, forgetfulness, internal restlessness — rather than the hyperactive-impulsive behaviors that trigger referral in boys. A 2019 review in BMC Psychiatry found that women received their ADHD diagnosis an average of 5 years later than men, and that prior to diagnosis, they were significantly more likely to have been treated for anxiety or depression. The same pattern is emerging for autism spectrum disorder, where diagnostic tools calibrated to male presentations miss women and girls who have developed masking behaviors.
Pain medicine. Chronic pain conditions that disproportionately affect women — fibromyalgia, chronic fatigue syndrome, temporomandibular disorders, interstitial cystitis — have historically received less research funding and are more likely to be classified as "functional" or "psychosomatic" than conditions with comparable symptom severity that affect both sexes equally.
Emergency medicine. A 2022 study in Emergency Medicine Journal tracked triage times across multiple hospitals and found that women waited an average of 16 minutes longer than men for pain medication in the emergency department, after controlling for pain severity, chief complaint, and acuity level.
Surgery. A 2021 analysis in JAMA Surgery found that women were less likely to be referred for surgical intervention for conditions including gallbladder disease, hernias, and joint replacement — and when referred, experienced longer wait times.
Autoimmune Diseases: The 80% Problem
Autoimmune diseases represent one of the starkest examples of the gender gap — not because medicine ignores them entirely, but because the field has been slow to reckon with why they affect women so disproportionately.
Of the approximately 100 identified autoimmune diseases, roughly 80% of cases occur in women. This includes lupus (9:1 female-to-male ratio), Sjogren's syndrome (9:1), Hashimoto's thyroiditis (10:1), and rheumatoid arthritis (3:1). Collectively, autoimmune diseases affect approximately 50 million Americans, making them one of the leading causes of disability in women.
The biological reasons for this disparity are still being investigated. A 2024 paper in Cell by Stanford researchers identified a molecular mechanism involving the X chromosome: a protein called Xist, which is produced only in cells with two X chromosomes, can trigger immune responses that attack the body's own tissues. This discovery may help explain why having two X chromosomes — the typical female karyotype — confers greater autoimmune susceptibility.
Despite the clear sex skew, autoimmune diseases remain notoriously difficult to diagnose. The symptoms — fatigue, joint pain, brain fog, intermittent rashes, gastrointestinal issues — are nonspecific and fluctuating, which means they are easily attributed to stress, depression, or somatization. The American Autoimmune Related Diseases Association reports that 45% of autoimmune patients were initially labeled as hypochondriacs or chronic complainers before receiving a correct diagnosis.
Early identification matters because many autoimmune conditions cause progressive organ damage that can be slowed or prevented with treatment — but only if treatment begins before irreversible damage has occurred. The diagnostic delay costs lives and quality of life.
The Maternal Health Crisis
The gender gap extends to the one area where you would expect medicine to center women's needs: pregnancy and childbirth.
The United States has the highest maternal mortality rate of any developed nation. According to the CDC, approximately 1,205 women died from maternal causes in 2021 — a rate of 32.9 deaths per 100,000 live births, more than double the rate of a decade earlier. For Black women, the rate was 2.6 times higher than for white women, illustrating how the gender gap intersects with racial disparities.
A significant proportion of these deaths are preventable. A 2022 report from the CDC's Maternal Mortality Review Committees found that 84% of pregnancy-related deaths had at least one contributing factor that represented a missed opportunity for intervention. The most common failures were: delayed response to warning signs (such as postpartum hemorrhage or preeclampsia), inadequate assessment, and poor coordination between providers.
Postpartum conditions are particularly neglected. Preeclampsia can persist or develop after delivery but is often missed because monitoring drops off dramatically once the baby is born. Postpartum depression affects an estimated 1 in 7 new mothers, yet screening is inconsistent and follow-up is poor. Postpartum thyroiditis, cardiomyopathy, and pelvic floor disorders are frequently undiagnosed because the clinical system's focus shifts entirely to the infant.
The World Health Organization has called maternal mortality a "litmus test" for the overall quality of a healthcare system. By that measure, many systems are failing.
Why Does This Persist? Structural Roots
The gender gap in healthcare is not the product of individual bad actors. It is a structural problem with identifiable causes.
Medical education. A 2018 analysis in Academic Medicine reviewed curricula at 60 US medical schools and found that sex- and gender-specific medicine received an average of 5 hours of dedicated instruction across four years of medical school. Many conditions with known sex differences — including cardiovascular disease, pain syndromes, and pharmacokinetics — were taught using male-default presentations without discussion of how symptoms or treatment responses differ in women.
Research funding. Despite women making up half the population and bearing a disproportionate burden of autoimmune disease, chronic pain, and mental health conditions, NIH spending on women's health remains a fraction of overall expenditure. The National Institutes of Health did not establish the Office of Research on Women's Health until 1990, and it was not until 2016 that the NIH implemented a policy requiring researchers to consider sex as a biological variable in preclinical studies.
Clinical guidelines. Many diagnostic algorithms and risk calculators were developed using predominantly male data. The Framingham Risk Score for cardiovascular disease, one of the most widely used clinical tools, was developed from a cohort that was originally entirely male. Although it has been updated, the fundamental architecture reflects its origins. Similar issues affect guidelines for conditions from kidney disease to concussion.
Implicit bias. The PNAS vignette study mentioned earlier demonstrates that even well-meaning clinicians are affected by unconscious assumptions about gender and pain. These biases are not easily corrected by awareness alone — they are baked into clinical culture through training, mentorship, and institutional norms.
Fragmented care. Women's healthcare is often siloed into "reproductive health" (managed by OB/GYNs) and "everything else" (managed by primary care and specialists). This fragmentation means that symptoms spanning multiple systems — exactly the pattern seen in autoimmune diseases, endometriosis, and hormonal disorders — are evaluated in pieces rather than as a whole.
What Is Changing: Signs of Progress
The picture is not entirely bleak. Several developments are pushing healthcare toward greater equity.
Research policy reforms. The NIH's 2016 policy requiring consideration of sex as a biological variable has begun to change the research landscape. A growing number of journals now require that studies report results disaggregated by sex. The European Medicines Agency has implemented similar requirements for drug approval submissions.
Sex-specific cardiology. Institutions including the Mayo Clinic, Cedars-Sinai, and Brigham and Women's Hospital have established dedicated women's heart health programs that use sex-specific risk assessment tools and diagnostic criteria. The American Heart Association launched its "Go Red for Women" campaign and has published updated guidelines acknowledging sex differences in presentation, treatment response, and outcomes.
Endometriosis awareness. Several countries have launched national action plans for endometriosis. France announced a national strategy in 2022, and Australia committed significant research funding in 2023. The development of non-invasive biomarkers for endometriosis — including blood tests and imaging algorithms — is a major research priority that could dramatically reduce diagnostic delays.
Precision medicine. The broader movement toward personalized medicine — tailoring treatment to individual characteristics rather than population averages — inherently benefits women by moving away from one-size-fits-all approaches developed using male-majority data. Pharmacogenomics, which studies how genetic variation affects drug response, is increasingly incorporating sex-specific analysis.
Medical education reform. A 2023 consensus statement from the Association of American Medical Colleges called for integrating sex and gender considerations throughout the medical curriculum rather than confining them to a single lecture. Several medical schools, including those at Brown University and the University of Virginia, have piloted sex-specific curricula in cardiology, pharmacology, and pain medicine.
What You Can Do: Practical Advocacy for Your Own Health
Systemic change takes time. In the meanwhile, there are evidence-based strategies for navigating a healthcare system that may not be calibrated to your body.
Document your symptoms systematically. One of the most powerful tools against diagnostic dismissal is a detailed, timestamped record of your symptoms. When you walk into a doctor's office with a clear log showing that your fatigue has persisted for six months, that your pain follows a specific pattern, or that your mood changes correlate with your cycle, it is much harder for a clinician to wave you away with a "probably stress" explanation. WatchMyHealth's symptom tracking, wellbeing logging, and pain journal features are designed for exactly this purpose — building a longitudinal record that speaks in the data-driven language clinicians respect.
Learn the language. Research shows that patients who use specific medical terminology in describing their symptoms receive more thorough evaluations. Instead of "I feel tired all the time," try: "I have persistent fatigue unrelieved by sleep, lasting more than six months, accompanied by cognitive difficulty and joint pain." You are describing the same experience, but in a framework that activates clinical pattern recognition.
Ask for documentation. If a provider declines to order a test or pursue a diagnosis, calmly ask them to document in your medical record that the test was requested and refused, along with their reasoning. This serves two purposes: it creates a paper trail if you later need to demonstrate a pattern of delayed diagnosis, and it often prompts the provider to reconsider — because the act of documenting a refusal makes them weigh the decision more carefully.
Request specific tests by name. If you have done your research — and you should — ask for the specific diagnostic tests relevant to your symptoms. For suspected endometriosis, ask about transvaginal ultrasound and referral to an endometriosis specialist. For cardiac symptoms, ask about a troponin test and an ECG. For autoimmune suspicion, ask about ANA, CRP, and ESR panels. You should not have to do this, but until the system catches up, knowledge is protection.
Bring data to your appointments. If you have been tracking your health over time — symptoms, medications, pain levels, cycle patterns, mood — bring that data. Export it, print it, or share it on your phone. WatchMyHealth allows you to export your health data in formats you can share with your doctor, turning months of subjective experience into objective evidence. This is especially valuable when symptoms are intermittent or cyclical, because a single appointment snapshot may not capture the full picture.
Get a second opinion. If your symptoms are persistent and your current provider attributes them to anxiety or stress without investigation, seek another opinion. This is not doctor-shopping — it is appropriate medical self-advocacy. The diagnostic delay statistics cited throughout this article exist precisely because patients accepted initial reassurance that turned out to be wrong.
Navigating the System as a Team
Advocacy should not fall entirely on the patient. Partners, family members, and friends can play a critical role.
Research from a 2020 study in Health Affairs found that women were more likely to have their symptoms taken seriously when accompanied by another person to appointments — particularly when that person corroborated the symptom history. This should not be necessary, but it is a pragmatic tool in a flawed system.
If you are supporting someone who is struggling to get a diagnosis:
Believe their symptoms. Before anything else, validate their experience. The most damaging aspect of diagnostic dismissal is the self-doubt it creates. When the medical system tells you nothing is wrong but your body says otherwise, having someone in your corner who says "I see what you are going through" is more valuable than it might seem.
Help document patterns. Offer to help them keep a symptom log. Note what you observe — changes in energy, sleep, function, mood — that they may have normalized or stopped reporting because they have been told it is not significant.
Accompany them to appointments. Your presence can change the dynamic. You can take notes, ask follow-up questions, and serve as a witness to what was said and recommended.
Research together. Help them identify specialists who have expertise in their suspected condition. Patient advocacy organizations for conditions like endometriosis, lupus, ADHD, and PCOS often maintain directories of recommended providers.
The Role of Technology and Self-Tracking
One of the most significant shifts in healthcare over the past decade has been the rise of patient-generated health data. Wearable devices, health apps, and digital symptom trackers are putting longitudinal health data directly into patients' hands — and this has particular implications for women navigating the gender gap.
Consider the diagnostic journey for endometriosis. The average 8-to-10-year delay often involves visits to multiple providers, none of whom see the full picture because they only have access to their own notes. A patient who has been tracking her pain patterns, menstrual cycles, fatigue levels, and medication responses over months or years carries a complete clinical narrative that no single provider's chart can match.
The same applies to autoimmune diseases, where symptoms wax and wane unpredictably. A rheumatologist seeing you on a "good day" may not appreciate the severity of your condition — but a six-month trend line showing progressive fatigue, increasing joint stiffness, and declining wellbeing scores tells a story that a single appointment cannot.
WatchMyHealth's AI health coach can also help identify patterns you might not notice yourself — correlations between stress and symptom flares, relationships between sleep quality and pain levels, or gradual changes in wellbeing that are invisible day-to-day but obvious over weeks and months. These data-driven insights give you a stronger foundation for clinical conversations and can help a new provider get up to speed quickly without starting from scratch.
This is not about replacing clinical judgment with an app. It is about giving patients — particularly patients whose reports are routinely undervalued — the tools to present their experience as data rather than anecdote.
Looking Ahead: What Needs to Change
Closing the gender gap in healthcare will require coordinated action across multiple fronts.
In research: Clinical trials must achieve true demographic parity — not as a quota but as a scientific necessity. The biological differences between male and female bodies are not confounding variables to be controlled away. They are fundamental features of human physiology that affect how every drug, device, and intervention works. The FDA's 2022 draft guidance on diversity action plans for clinical trials is a step forward, but enforcement mechanisms remain weak.
In education: Medical schools need to integrate sex and gender considerations throughout the curriculum, not as an elective add-on but as a core component of how every disease, drug, and diagnostic approach is taught. Every student who graduates without knowing that women's heart attacks can present as jaw pain and nausea is a student who will one day send a woman home with an anxiety leaflet.
In clinical practice: Diagnostic algorithms and risk scores need to be validated separately in women. Clinical guidelines should explicitly address sex differences in presentation, treatment response, and adverse effects. And implicit bias training needs to move beyond one-off workshops to become an ongoing component of professional development.
In funding: Conditions that disproportionately affect women — endometriosis, autoimmune diseases, chronic pain syndromes, maternal health complications — need research funding proportional to their disease burden. The current allocation does not reflect the scale of suffering.
In culture: The normalization of women's pain — the cultural assumption that menstrual cramps are "just part of being a woman," that fatigue is "just stress," that mood changes are "just hormones" — must be challenged. Pain is a clinical signal, not a character trait. Fatigue is a symptom, not a personality flaw.
The gender gap in healthcare is not inevitable. It is the product of choices — about who gets studied, what gets funded, how symptoms get evaluated, and whose pain gets believed. Different choices can produce different outcomes. The evidence for that is as strong as the evidence for the gap itself.
